Academic literature on the topic 'In silico oncology'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'In silico oncology.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "In silico oncology"
1
Abler, D., P. Büchler, and G. S. Stamatakos. "CHIC – A Multi-scale Modelling Platform for in-silico Oncology." Radiotherapy and Oncology 118 (February 2016): S1. http://dx.doi.org/10.1016/s0167-8140(16)30001-9.
Full text
2
Kim, Eugene, Samantha Duarte, Stas Fridland, Myungwoo Nam, Jin Young Hwang, Alice Daeun Lee, Grace Lee, Emma Yu, and Young Kwang Chae. "Evaluation of in silico tools for variant classification in clinically actionable NSCLC variants." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e13545-e13545. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e13545.
Full textAbstract:
e13545 Background: Genetic variants beyond FDA-approved drug targets are often identified in NSCLC patients. To address this challenge, in silico variant classification tools are available to determine whether specific variants contribute to disease pathogenicity or remain benign. Although the performance of in silico tools has been analyzed in previous studies, it has not been analyzed for actionable targets of FDA-approved therapies for NSCLC. The aim of this study is to compare the performance of commonly used in silico tools in classifying the pathogenicity of actionable variants in NSCLC. Methods: We evaluated the performance of several in silico tools: PolyPhen-2, Align-GVGD, and MutationTaster2. A curated set of targetable NSCLC missense variants (n = 179) was used. The dataset consisted of variants in the BRAF, EGFR, ERBB2, KRAS, MET, ALK, and ROS1 genes based on their indications as molecular targets in the NCCN Guidelines for NSCLC. Pathogenic variants (n = 80) were curated based on available literature and annotations according to the NCCN Guidelines, OncoKB, My Cancer Genome, and AACR Project GENIE. Benign variants (n = 99) were curated from the dbSNP database with the inclusion criteria of a benign or likely benign ClinVar assertion. The overall accuracy, sensitivity, specificity, and Matthews correlation coefficient (MCC) of each in silico tool were determined. The performance of each in silico tool in predicting pathogenicity for subsets of sensitizing (n = 18) and resistant (n = 57) variants was also evaluated. Results: PolyPhen-2 HumVar demonstrated the highest overall accuracy (0.80), specificity (0.69), and MCC (0.63) of the in silico tools analyzed. PolyPhen-2 HumDiv (0.75) and MutationTaster2 (0.69) had similar overall accuracies while Align-GVGD (0.50) had the lowest overall accuracy. Align-GVGD also had the lowest MCC (0.08), with the other in silico tools ranging from 0.50 to 0.63. All the in silico tools achieved high sensitivities, with MutationTaster2 performing the highest (1.00) and Align-GVGD performing the lowest (0.86). The specificities were remarkably low (0.20-0.69) for all the in silico tools, with the lowest specificity demonstrated by Align-GVGD. The overall accuracies when classifying the subsets of sensitizing and resistant variants were generally high, ranging from 0.84 to 1.00. Conclusions: These results suggest that the performance of the evaluated in silico tools to predict the pathogenicity of clinically actionable NSCLC missense variants is not fully reliable. The tools analyzed in this study could be acceptable to rule out pathogenicity in variants given their higher sensitivities, but are limited when it comes to identifying pathogenicity in variants due to low specificities.
3
Johnson, David, Steve McKeever, Georgios Stamatakos, Dimitra Dionysiou, Norbert Graf, Vangelis Sakkalis, Konstantinos Marias, Zhihui Wang, and Thomas S. Deisboeck. "Article Commentary: Dealing with Diversity in Computational Cancer Modeling." Cancer Informatics 12 (January 2013): CIN.S11583. http://dx.doi.org/10.4137/cin.s11583.
Full textAbstract:
This paper discusses the need for interconnecting computational cancer models from different sources and scales within clinically relevant scenarios to increase the accuracy of the models and speed up their clinical adaptation, validation, and eventual translation. We briefly review current interoperability efforts drawing upon our experiences with the development of in silico models for predictive oncology within a number of European Commission Virtual Physiological Human initiative projects on cancer. A clinically relevant scenario, addressing brain tumor modeling that illustrates the need for coupling models from different sources and levels of complexity, is described. General approaches to enabling interoperability using XML-based markup languages for biological modeling are reviewed, concluding with a discussion on efforts towards developing cancer-specific XML markup to couple multiple component models for predictive in silico oncology.
4
Graf, N., A. Hoppe, E. Georgiadi, R. Belleman, C. Desmedt, D. Dionysiou, M. Erdt, et al. "‘In Silico’ Oncology for Clinical Decision Making in the Context of Nephroblastoma." Klinische Pädiatrie 221, no. 03 (March 2009): 141–49. http://dx.doi.org/10.1055/s-0029-1216368.
Full text
5
Stamatakos, G. S., D. D. Dionysiou, E. I. Zacharaki, N. A. Mouravliansky, K. S. Nikita, and N. K. Uzunoglu. "In silico radiation oncology: combining novel simulation algorithms with current visualization techniques." Proceedings of the IEEE 90, no. 11 (November 2002): 1764–77. http://dx.doi.org/10.1109/jproc.2002.804685.
Full text
6
Filippova, Darya, Matthew H. Larson, M. Cyrus Maher, Robert Calef, Monica Pimentel, Yiqi Zhou, Joshua Newman, et al. "The Circulating Cell-free Genome Atlas (CCGA) Study: Size selection of cell-free DNA (cfDNA) fragments." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 3103. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3103.
Full textAbstract:
3103 Background: Detection of somatic copy number aberrations in individuals with cancer via cfDNA whole-genome sequencing (WGS) is challenging at low tumor fractions. Given that tumor-derived cfDNA fragments are shorter than those from healthy tissues, this exploratory analysis evaluated the potential effect of size selection on the ability to detect cancer. Methods: CCGA WGS libraries were in silico and in vitro size selected to estimate the change in tumor fraction by tumor types (breast, lung, and colorectal [CRC]) and stage (I-III vs IV). In silico analyses used clinically evaluable training set samples with WGS assay results (n = 1422: 560 non-cancer [NC], 862 cancer [C] stages I-IV); classification (cancer/non-cancer) performance was estimated using fragments within the 90-150 bp range. In vitro analyses used a subset of samples (n = 93: 28 NC, 65 C stages I-IV), including C cases sampled within a range of tumor fractions; tumor fraction was also measured at each progressive removal of maximum-length fragments (intervals of 10 bp: 150 bp down to 50 bp). Results: In silico and in vitro analyses, respectively, resulted in median 2.00±0.58-fold (at 6.91±2.64X depth) and 2.00±0.52-fold (at 23±4.45X depth) increases, in overall tumor fraction (compared to non-size-selected 36X depth). This was consistent across tumor types ( in silico: 1.78±0.73 breast, 2.00±0.58 CRC, 2.00±0.41 lung; in vitro: 2.00±0.82 breast, 2.51±0.52 CRC, 2.53±0.94 lung) and stages ( in silico: 2.00±0.74 I-III, 1.78±0.52 IV; in vitro: 2.00±0.55 I-III, 1.68±0.29 IV). Tumor fraction increased with initial fragment length titrations, but not following size selection to shorter lengths ( < 140 bp). Classifier trained on in silico size-selected data had increased sensitivity at 98% specificity compared to those trained on non-size-selected data (p < 1e-5). Conclusions: In silico and in vitro size selection consistently increased tumor fraction across cancer types and stages, and this increase was maximized by tuning the length range of size selection. Relative to full-depth data, classification performance improved significantly. These data suggest that size selection targeting cfDNA under 140 bp may enhance cfDNA-based cancer detection. Clinical trial information: NCT02889978.
7
Minussi, Darlan Conterno, Bernardo Henz, Mariana dos Santos Oliveira, Eduardo C. Filippi-Chiela, Manuel M. Oliveira, and Guido Lenz. "esiCancer: Evolutionary In Silico Cancer Simulator." Cancer Research 79, no. 5 (December 18, 2018): 1010–13. http://dx.doi.org/10.1158/0008-5472.can-17-3924.
Full text
8
Jackson, Robert C. "Pharmacodynamic Modelling of Biomarker Data in Oncology." ISRN Pharmacology 2012 (February 16, 2012): 1–12. http://dx.doi.org/10.5402/2012/590626.
Full textAbstract:
The development of pharmacodynamic (PD) biomarkers in oncology has implications for design of clinical protocols from preclinical data and for predicting clinical outcomes from early clinical data. Two classes of biomarkers have received particular attention. Phosphoproteins in biopsy samples are markers of inhibition of signalling pathways, target sites for many novel agents. Biomarkers of apoptosis in plasma can measure tumour cell killing by drugs in phase I clinical trials. The predictive power of PD biomarkers is enhanced by data modelling. With pharmacokinetic models, PD models form PK/PD models that predict the time course both of drug concentration and drug effects. If biomarkers of drug toxicity are also measured, the models can predict drug selectivity as well as efficacy. PK/PD models, in conjunction with disease models, make possible virtual clinical trials, in which multiple trial designs are assessed in silico, so the optimal trial design can be selected for experimental evaluation.
9
Katoh, Masuko, and Masaru Katoh. "Characterization of human ARHGAP10 gene in silico." International Journal of Oncology 25, no. 4 (October 1, 2004): 1201–7. http://dx.doi.org/10.3892/ijo.25.4.1201.
Full text
10
Hede, K. "In Silico Research: Pushing It Into the Mainstream." JNCI Journal of the National Cancer Institute 102, no. 4 (February 9, 2010): 217–19. http://dx.doi.org/10.1093/jnci/djq035.
Full textDissertations / Theses on the topic "In silico oncology"
1
Connor, Anthony J. "In silico modelling of tumour-induced angiogenesis." Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:f6b6c496-3adb-43c4-a3b3-aaf4d1b866b4.
Full textAbstract:
Angiogenesis, the process by which new vessels form from existing ones, is a key event in the development of a large and malignant vascularised tumour. A rapid expansion in in vivo and in vitro angiogenesis research in recent years has led to increased knowledge about the processes underlying angiogenesis and to promising steps forward in the development of anti-angiogenic therapies for the treatment of various cancers. However, substantial gaps in knowledge persist and the development of effective treatments remains a major challenge. In this thesis we study tumour-induced angiogenesis within the context of a highly controllable experimental environment: the cornea micropocket assay. Using a multidisciplinary approach that combines experiments, image processing and analysis, and mathematical and computational modelling, we aim to provide mechanistic insight into the action of two angiogenic factors which are known to play central roles during tumour-induced angiogenesis: vascular endothelial growth factor A (VEGF-A) and basic fibroblast growth factor (bFGF). Image analysis techniques are used to extract quantitative data, which are both spatially and temporally resolved, from experimental images. These data are then used to develop and parametrise mathematical models describing the evolution of the corneal vasculature in response to both VEGF-A and bFGF. The first models developed in this thesis are one-dimensional continuum models of angiogenesis in which VEGF-A and/or bFGF are released from a pellet implanted into a mouse cornea. We also use an object-oriented framework, designed to facilitate the re-use and extensibility of hybrid multiscale models of angiogenesis and vascular tumour growth, to develop a complementary three-dimensional hybrid model of the same system. The hybrid model incorporates a new non-local cell sensing model which facilitates the formation of well-perfused and functional vascular networks in three dimensions. The continuum models are used to assess the utility of the cornea micropocket assay as a quantitative assay for angiogenesis, to characterise proposed synergies between VEGF-A and bFGF, and to generate experimentally testable predictions regarding the effect of anti-VEGF-A therapies on bFGF-induced angiogenesis. Meanwhile, the hybrid model is used to provide context for the comparison that is drawn between the continuum models and the data, to study the relative distributions of perfused and unperfused vessels in the evolving neovasculature, and to investigate the impact of tip cell sensing dysregulation on the angiogenic response in the cornea. We have found that by exploiting a close link with quantitative data we have been able to extend the predictive and hypothesis-testing capabilities of our models. As such, this thesis demonstrates the potential for integrating mathematical modelling with image analysis techniques to increase insight into the mechanisms underlying angiogenesis.
2
Battaglia, Sebastiano. "Nuclear receptor co-repressor functions in prostate cancer : in vitro, in vivo and in silico approaches." Thesis, University of Birmingham, 2010. http://etheses.bham.ac.uk//id/eprint/961/.
Full textAbstract:
Prostate epithelial cells are exquisitely sensitive to Nuclear Receptor (NR) ligands. These compounds exert anti-proliferative effect over non-malignant cells RWPE-1 while malignant PC-3 cells retain their proliferative ability. The Nuclear Receptor Co-Repressor 1 (NCOR1) complexes with Histone Deacetylases (HDACs) to repress the action of unliganded NRs, hence, inhibiting their transcriptional and phenotypical effects. NCOR1 was found to be over-expressed in PC-3 cells when compared to non-malignant RWPE-1 cells. Chemical inhibition of NCOR1, via the HDAC inhibitor SAHA, or NCOR1 knock-down, via shRNA, restored PC-3 cells sensitivity to NR agonists with exception of Vitamin D and Thyroid Hormone T3. NCOR1-knock down led also to a re-expression of basally repressed genes, as measured via Microfluidic Gene-Card analysis (Q-RTPCRm). CDKN1A was de-repressed by the knock down and its activation via VDR was modeled with a systems biology approach to identify the mechanistic events behind CDKN1A transcriptional regulation via miRNAs. Differential equation models revealed a time-sensitive activation, VDR-dependent, of the miRNA-miR106b that leads to a steep degradation of CDKN1A mRNA levels within the first 30 minutes. These results support the idea of a corrupted regulatory network that squelches NR activity in prostate epithelial cells.
3
Haddow, Sarah Louise. "Perylene derivatives and silicon nanosheets." Thesis, University of Nottingham, 2017. http://eprints.nottingham.ac.uk/41873/.
Full textAbstract:
The work presented in this thesis explores two different topics of interest, firstly a synthetic project fabricating small building blocks for supramolecular arrays. The building blocks are a series of perylene monoimide monoahydride (PMIA) compounds, synthesised by a four step process. The PMIA compounds belong to a family of dyes called the rylenes which are known in literature for their optical properties and use in optoelectronic devices. Chapter 2 begins with the description of the synthesis and characterisation of these molecules, where Hirshfeld surface analysis is used to investigate the solid state intermolecular forces between adjacent molecules. This is followed by the details of connecting two PMIA through organic linkers and it explores the structural and physical properties of the so called dimer. The physical properties investigated include, optical and electronic properties utilizing spectroelectrochemistry, cyclic voltammetry and electron paramagnetic resonance techniques. The chapter also explores the asymmetric feature of the building blocks with the aid of X-ray crystallography. The second topic of interest is silicon nanosheets (SiNS). There are many types of these two dimensional (2D) materials published in literature, however one type which has had minimal attention is a buckled sheet structure known as layered polysilane. A synthetic and structural investigation into layered polysilane and closely related siloxene, are carried out in Chapter 3, identifying their bonding arrangement and topographic assembly through a range of analytical techniques. Like many other SiNS, it is proposed that this material can be used in nanotechnology devices in the future, and this thesis makes some way towards identifying the structure which is important in order to use them in such devices. Chapter 4 leads on to discuss the investigation into the modification of SiNS fabricated in Chapter 3, via a range of small organic molecules. This is another area in literature which has great scope for investigation and exciting potential for use in nanodevices. An important difference once the SiNS have been functionalised with small organic groups is their enhanced solubility, in comparison to being insoluble before functionalisation. This opens up a wealth of applications which require solution phase activity. A range of surface analytical techniques aid in identification of functionalised sheets and Chapter 4 details the challenges and successes.
4
Valença, João Vinícius Batista. "Avaliação de um simulador de mama para estudo da interferência do implante de silicone na visualização de achados mamográficos." Pós-Graduação em Física, 2012. https://ri.ufs.br/handle/riufs/5364.
Full textAbstract:
The establishment of specific equipment with the only purpose of evaluation the breast
tissue has brought important improvement in mammary cancer detection. Presenting a huge
variety in its characteristics, the female breasts varies in density and also in thickness, the
mammographer it is useful in many occasions, including breast with artificial implants. The
goal of this work is evaluate, using as main parameters the effective atomic number (Zef) and
the total mass attenuation coefficient (ì/ñ), the mixture between paraffin gel and acrylic
powder as breast simulator, as well as use the best proportion of these materials to analyze the
interference of the silicone implant in images. Showing a rapid manufacture procedure, and
requiring low cost materials, the simulator built with the proportion Paraffin+10%acrylic ,
which represents the addition of 10% of acrylic in the value of the paraffin, was the one that
simulated best the mammary glands. The adipose tissue, which the proximity was greater, the
percentage differences obtained to ì/ñ were approximately 32,9% for 10keV, 28,5% for
15 keV, 20,2% for 20 KeV, 11,1% for 30 keV e 5,4% for 40 keV. The evaluation in terms of
implant interference showed that the scattered radiation produced by it has an approximated
range of 5 mm to the built simulator which was introduced a 105 mL implant. Exposures with
different compressions characteristics also were made, which was clear the influence in the
image with quality and less time exposureO estabelecimento de um equipamento especifico para avaliação da mama com uso da radiação X trouxe importantes beneficios na deteccao precoce do câncer mamário. Apresentando-se com diversas características, a mama feminina varia em relação tanto a densidade como em espessura, sendo o mamografo util em diversas analises, incluindo em mamas portadoras de implantes artificiais. O objetivo deste trabalho foi avaliar uma mistura entre parafina em gel e acrilico em po como simulador do tecido mamario, usando como parametros principais o numero atomico efetivo (Zef) e o coeficiente de atenuacao massico total ( Ê/ Ï), bem como utilizar a melhor proporcao destes para analisar a interferencia na imagem da presenca do implante de silicone. Empregando processo de confeccao rapido, e utilizando materiais de baixo valor monetario, o simulador construido com a proporcao eParafina + 10% acrilico f, que representa adicao de acrilico no valor de 10% do valor da parafina utilizado, foi aquele que melhor simulou a glandula mamaria. Em relacao ao tecido adiposo, no qual a proximidade de simulacao foi maior, as diferencas percentuais exibidas para Ê/ Ï foram de aproximadamente 32,9% para 10 keV, 28,5% para 15 keV, 20,2% para 20 keV, 11,1% para 30 keV e 5,4% para 40 keV. A avaliacao em termos da interferencia do implante de 105 mL mostrou que a radiacao espalhada por ele dentro do objeto simulador tinha um alcance aproximado de 5 mm. Exposicoes com diferentes caracteristicas de compressao tambem foram efetuadas e por meio da analise das imagens obtidas ficou evidente a influencia da compressao na obtencao de imagens com boa qualidade sendo necessario um menor tempo de exposição
5
França, Diurianne Caroline Campos [UNESP]. "Avaliação da biocompatibilidade de vários elastômeros de silicone implantados no tecido subcutâneo de ratos: estudo histológico e histomorfométrico." Universidade Estadual Paulista (UNESP), 2005. http://hdl.handle.net/11449/91431.
Full textAbstract:
Made available in DSpace on 2014-06-11T19:25:20Z (GMT). No. of bitstreams: 0
Previous issue date: 2005-08-22Bitstream added on 2014-06-13T19:11:58Z : No. of bitstreams: 1
franca_dcc_me_araca.pdf: 2609587 bytes, checksum: 8a7904cdb64c406b06f726af6ac60fbc (MD5)Universidade Estadual Paulista (UNESP)
No presente estudo foram utilizados 60 ratos submetidos a implantes subcutâneos de quatro elastômeros de silicone, sendo três usados em prótese bucomaxilofacial, LIM 6050, MDX 4-4210 e Silastic 732 RTV industrial e um indicado para cirurgia plástica, o Silimed. O objetivo do estudo foi avaliar os materiais em relação à compatibilidade biológica tecidual, nos tempos pós-operatórios de sete, quinze e trinta dias, quando os animais foram sacrificados e as peças processadas e coradas pela hematoxilina e eosina para análise qualitativa e quantitativa dos espécimes. Pelo estudo histomorfométrico, oito áreas de 60,11 mm2 foram analisadas, contando-se as células mesenquimais, inflamatórias mononucleares, eosinófilos e as células gigantes do tipo corpo estranho. O experimento foi desenvolvido em dois capítulos, estudando-se separadamente os silicones de uso em prótese e o Silimed. No primeiro capítulo, a análise da biocompatibilidade dos implantes subcutâneos dos elastômeros de silicone LIM 6050, MDX 4-4210 e Silastic 732 RTV industrial, observou-se biocompatibilidade aceitável em todos eles, considerando-se o fato de que sua indicação protética dependeria em especial das características físicas próprias de cada material, pela mínima reação tecidual observada, além de que em sua forma sólida é fácil a adaptação aos tecidos. No segundo capítulo, o estudo se baseou na análise das reações referentes ao implante de silicone utilizado em cirurgia plástica (Silimed), constatando-se a presença de processo inflamatório ligeiramente maior no silicone gel em relação aos outros grupos, porém com níveis aceitáveis de biocompatibilidade, confirmada pela rara presença de células gigantes do tipo corpo estranho. Todos os dados foram submetidos à análise de variância e teste de Tukey, demonstrando que todos os materiais implantados iniciaram uma resposta...
In the present study 60 rats were submitted to subcutaneous implant of four elastomers of silicon, being three of use in bucomaxillofacial prosthesis, LIM 6050, MDX 4-4210 and Silastic 732 RTV industrial and a suitable one for plastic surgery, Silimed. The objective of the study was to evaluate the materials in relation to the tissue biological compatibility, in the postoperative times of seven, fifteen and thirty days, when the animals were sacrificed and the processed pieces and stained for the hematoxilin and eosin for qualitative and quantitative analysis of the specimens. For the histomorphometric study, eight areas of 60,11 mm2 were analyzed, being counted the mesenchimal cells, inflammatory cells, eosinophile and giant cells. The experiment was developed in two chapters, being studied the use silicons separately in prosthesis and Silimed. In the first chapter, the analysis of the biocompatibility of the subcutaneous implant of the elastomers of silicon LIM 6050, MDX 4-4210 and Silastic 732 RTV industrial, acceptable biocompatibility was observed in all of them, being considered the fact that your prosthetic indication would especially depend on the own physical characteristics of each material, for the low tissue reaction observed, in addition in your solid form it is easy the adaptation to the tissues. In the second chapter, the study based on the analysis of the referring reactions to the it implants of silicon used in plastic surgery (silimed), being verified the presence of inflammatory process lightly larger in relation to the other groups, however with acceptable levels of biocompatibility confirmed by the rare presence of giant cells of the type strange body. All the data were submitted to the variance analysis and test of Tukey, demonstrating that all the implanted materials began an acceptable tissue inflammatory reaction, with tissue reactions of light intensity the moderate... (Complete abstract, click electronic address below)
6
Simon, Virginie. "Oncology nanomedicine : study of interaction between nanoparticles activated by external electromagnetic energy sources and cancer cells for enhancement of the therapeutic window." Paris 6, 2009. http://www.theses.fr/2009PA066708.
Full textAbstract:
La compréhension des interactions entre les nanomatériaux et les entités biologiques est fondamentale pour développer des nanoproduits en oncologie. NBTXR3 (nanoparticule inerte d’oxyde d’hafnium) et protoporphyrine IX (Pp IX) nanotransporteur (nanoparticule de silice encapsulant le Pp IX, le monomère du Photofrin®) sont des nanoproduits, issus des plateformes Nanobiotix, développés pour élargir la fenêtre thérapeutique des traitements du cancer en utilisant des sources d’activation externe de type « on » / « off ». La première partie de ce travail présente l’étude de l’interaction de NBTXR3 avec des cellules tumorales coliques humaines. NBTXR3 pénètre par endocytose et persiste dans le compartiment endo-lysosomial. Une augmentation significative de la réponse cellulaire à la radiothérapie est démontrée après activation de NBTXR3 par des radiations ionisantes. L’irradiation des cellules traitées par NBTXR3 entraîne des modifications spécifiques de leur morphologie par rapport aux contrôles; elles sont décrites ici. Une deuxième partie présente la synthèse d’un nouvel hybride pour la thérapie photodynamique, le Pp IX nanotransporteur, et étudie son interaction in vitro avec six lignées de cellules tumorales humaines et in vivo dans un modèle de souris nude xénogreffée avec trois types tumoraux. In vitro, le Pp IX nanotransporteur activé à 630 nm est plus efficace que le Pp IX libre. De plus, ce nouvel hybride favorise la biodistribution du Pp IX, avec une cinétique d’accumulation tumorale différente entre les modèles. La compréhension des interactions entre nanoparticules et cellules cancéreuses, apportée par ce travail, contribue à la création de nanothérapies innovantes.
7
França, Diurianne Caroline Campos. "Avaliação da biocompatibilidade de vários elastômeros de silicone implantados no tecido subcutâneo de ratos : estudo histológico e histomorfométrico /." Araçatuba : [s.n.], 2005. http://hdl.handle.net/11449/91431.
Full textAbstract:
Orientador: Alvimar Lima de CastroBanca: Hélio Massaiochi Tanimoto
Banca: Ana Maria Pires Soubhia
Resumo: No presente estudo foram utilizados 60 ratos submetidos a implantes subcutâneos de quatro elastômeros de silicone, sendo três usados em prótese bucomaxilofacial, LIM 6050, MDX 4-4210 e Silastic 732 RTV industrial e um indicado para cirurgia plástica, o Silimed. O objetivo do estudo foi avaliar os materiais em relação à compatibilidade biológica tecidual, nos tempos pós-operatórios de sete, quinze e trinta dias, quando os animais foram sacrificados e as peças processadas e coradas pela hematoxilina e eosina para análise qualitativa e quantitativa dos espécimes. Pelo estudo histomorfométrico, oito áreas de 60,11 mm2 foram analisadas, contando-se as células mesenquimais, inflamatórias mononucleares, eosinófilos e as células gigantes do tipo corpo estranho. O experimento foi desenvolvido em dois capítulos, estudando-se separadamente os silicones de uso em prótese e o Silimed. No primeiro capítulo, a análise da biocompatibilidade dos implantes subcutâneos dos elastômeros de silicone LIM 6050, MDX 4-4210 e Silastic 732 RTV industrial, observou-se biocompatibilidade aceitável em todos eles, considerando-se o fato de que sua indicação protética dependeria em especial das características físicas próprias de cada material, pela mínima reação tecidual observada, além de que em sua forma sólida é fácil a adaptação aos tecidos. No segundo capítulo, o estudo se baseou na análise das reações referentes ao implante de silicone utilizado em cirurgia plástica (Silimed), constatando-se a presença de processo inflamatório ligeiramente maior no silicone gel em relação aos outros grupos, porém com níveis aceitáveis de biocompatibilidade, confirmada pela rara presença de células gigantes do tipo corpo estranho. Todos os dados foram submetidos à análise de variância e teste de Tukey, demonstrando que todos os materiais implantados iniciaram uma resposta... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: In the present study 60 rats were submitted to subcutaneous implant of four elastomers of silicon, being three of use in bucomaxillofacial prosthesis, LIM 6050, MDX 4-4210 and Silastic 732 RTV industrial and a suitable one for plastic surgery, Silimed. The objective of the study was to evaluate the materials in relation to the tissue biological compatibility, in the postoperative times of seven, fifteen and thirty days, when the animals were sacrificed and the processed pieces and stained for the hematoxilin and eosin for qualitative and quantitative analysis of the specimens. For the histomorphometric study, eight areas of 60,11 mm2 were analyzed, being counted the mesenchimal cells, inflammatory cells, eosinophile and giant cells. The experiment was developed in two chapters, being studied the use silicons separately in prosthesis and Silimed. In the first chapter, the analysis of the biocompatibility of the subcutaneous implant of the elastomers of silicon LIM 6050, MDX 4-4210 and Silastic 732 RTV industrial, acceptable biocompatibility was observed in all of them, being considered the fact that your prosthetic indication would especially depend on the own physical characteristics of each material, for the low tissue reaction observed, in addition in your solid form it is easy the adaptation to the tissues. In the second chapter, the study based on the analysis of the referring reactions to the it implants of silicon used in plastic surgery (silimed), being verified the presence of inflammatory process lightly larger in relation to the other groups, however with acceptable levels of biocompatibility confirmed by the rare presence of giant cells of the type strange body. All the data were submitted to the variance analysis and test of Tukey, demonstrating that all the implanted materials began an acceptable tissue inflammatory reaction, with tissue reactions of light intensity the moderate... (Complete abstract, click electronic address below)
Mestre
8
Virginie, Simon. "NANOMEDECINE EN ONCOLOGIE : Etude des Interactions Entre les Nanoparticules Activables par des Sources d'Energie Electromagnétique Externes et les Cellules Cancéreuses pour Elargir la Fenêtre Thérapeutique." Phd thesis, Université Pierre et Marie Curie - Paris VI, 2009. http://tel.archives-ouvertes.fr/tel-00831605.
Full textAbstract:
La compréhension des interactions entre les nanomatériaux et les entités biologiques est fondamentale pour développer des nanoproduits en oncologie. NBTXR3 (nanoparticule inerte d'oxyde d'hafnium) et protoporphyrine IX (Pp IX) nanotransporteur (nanoparticule de silice encapsulant le Pp IX, le monomère du Photofrin®) sont des nanoproduits, issus des plateformes Nanobiotix, développés pour élargir la fenêtre thérapeutique des traitements du cancer en utilisant des sources d'activation externe de type " on " / " off ". La première partie de ce travail présente l'étude de l'interaction de NBTXR3 avec des cellules tumorales coliques humaines. NBTXR3 pénètre par endocytose et persiste dans le compartiment endolysosomial. Une augmentation significative de la réponse cellulaire à la radiothérapie est démontrée après activation de NBTXR3 par des radiations ionisantes. L'irradiation des cellules traitées par NBTXR3 entraîne des modifications spécifiques de leur morphologie par rapport aux contrôles; elles sont décrites ici. Une deuxième partie présente la synthèse d'un nouvel hybride pour la thérapie photodynamique, le Pp IX nanotransporteur, et étudie son interaction in vitro avec six lignées de cellules tumorales humaines et in vivo dans un modèle de souris nude xénogreffée avec trois types tumoraux. In vitro, le Pp IX nanotransporteur activé à 630 nm est plus efficace que le Pp IX libre. De plus, ce nouvel hybride favorise la biodistribution du Pp IX, avec une cinétique d'accumulation tumorale différente entre les modèles. La compréhension des interactions entre nanoparticules et cellules cancéreuses, apportée par ce travail, contribue à la création de nanothérapies innovantes.
9
Γεωργιάδη, Ελένη. "Τετραδιάστατη υπολογιστική προσομοίωση της ανάπτυξης στέρεων καρκινικών όγκων και της απόκρισης όγκων σε χημειοθεραπευτικά σχήματα : Εξατομίκευση και βελτιστοποίηση θεραπευτικών σχημάτων : Κλινικοί έλεγχοι του μοντέλου." Thesis, 2013. http://hdl.handle.net/10889/6315.
Full textAbstract:
Στόχος της διδακτορικής διατριβής είναι η ανάπτυξη ενός τετραδιάστατου προσομοιωτικού μοντέλου της ελεύθερης ανάπτυξης και απόκρισης όγκων νεφροβλαστώματος σε σχήματα χημειοθεραπείας. Το μοντέλο αναπτύχθηκε στα πλαίσια των εξής ευρωπαϊκών προγραμμάτων: ACGT (Advancing Clinicogenomic Trials on Cancer, FP6-2005-IST-026996), p-Medicine (From data sharing and integration via VPH models to Personalized medicine, FP7-ICT-2009-6-270089) και TUMOR (Transatlantic Tumour Model Repositories, FP7-ICT-2009.5.4). Το μοντέλο είναι κατά βάση διακριτό και κλινικά προσανατολισμένο . Κάνει σε μεγάλη έκταση, χρήση διακριτών οντοτήτων και διακριτών γεγονότων ενώ αναφέρεται σε πολλές χωροχρονικές κλίμακες της βιολογίας του καρκίνου. . Αποτελεί μια «από επάνω προς τα κάτω» (top-down) προσομοιωτική προσέγγιση. Ξεκινώντας από τα μακροσκοπικά απεικονιστικά δεδομένα ασθενών (υψηλό επίπεδο βιοπλοκότητας) και συνεχίζοντας προς τα επίπεδα χαμηλότερης πολυπλοκότητας. Ο κλινικός προσανατολισμός του μοντέλου αποτέλεσε τη βασική αρχή κατά την ανάπτυξή του. Τα διαθέσιμα ιατρικά δεδομένα αποσκοπούν στην εξατομίκευση της προσομοίωσης της συμπεριφοράς του όγκου για κάθε ασθενή. Το μοντέλο που αναπτύχθηκε στα πλαίσια του διδακτορικού, αποτελεί μέρος μιας σύνθετης αλγοριθμικής κατασκευής και ενός συστήματος βιοϊατρικής τεχνολογίας, του “Ογκοπροσομοιωτή”.
Έχουν πραγματοποιηθεί εκτεταμένοι έλεγχοι αξιοπιστίας του μοντέλου και παραμετρικές μελέτες. Η ανάλυση ευαισθησίας του μοντέλου αποκάλυψε ποιοί βιολογικοί μηχανισμοί παίζουν σημαντικό ρόλο στην εξέλιξη του όγκου. Αυτά τα συμπεράσματα μπορούν να παρέχουν περαιτέρω κατανόηση στη δυναμική της βιολογίας του καρκίνου.
Τα αρχικά αποτελέσματα των προσομοιώσεων της ελεύθερης ανάπτυξης και απόκρισης σε χημειοθεραπεία τυχαίου όγκου (ελλειψοειδούς) ενισχύουν σημαντικά την αξιοπιστία του μοντέλου.
H ήδη δημοσιευμένη προσαρμογή του μοντέλου σε πραγματικά περιστατικά κλινικών δοκιμών (SIOP 2001/GPOH) αποτελεί μια βάση δημιουργίας εμπιστοσύνης της επιστημονικής κοινότητας στο προσομοιωτικό δυναμικό της προσέγγισης. Για την κλινική προσαρμογή του συγκεκριμένου Ογκοπροσομοιωτή χρησιμοποιούνται τα διαθέσιμα κλινικά δεδομένα (απεικονιστικά, ιστοπαθολογικά), προ- και μετα-εγχειρητικά, σε συνδυασμό με τη διαθέσιμη πληροφορία από τη βιβλιογραφία. Η δυνατότητα να αξιοποιούνται άμεσα πρόσθετα δεδομένα στα πλαίσια κλινικών δοκιμών, περιορίζοντας έτσι το “παράθυρο” των πιθανών λύσεων αποτελεί ένα ιδιαίτερα ξεχωριστό χαρακτηριστικό του παρουσιαζόμενου μοντέλου.
Σημειώνεται ότι το μοντέλο βρίσκεται κάτω υπό συνεχή βελτιστοποίηση και επέκταση στα πλαίσια ευρωπαϊκών προγραμμάτων υπό υλοποίηση και κλινικών δοκιμών.The aim of this thesis is to develop a 4D spatiotemporal simulation model of the free growth of Wilms’ tumours and its response to chemotherapeutic regimens. The model has been developed within the framework of three EC-funded projects: ACGT (Advancing Clinicogenomic Trials on Cancer, FP6-2005-IST-026996), p-Medicine (From data sharing and integration via VPH models to Personalized medicine, FP7-ICT-2009-6-270089) and TUMOR (Transatlantic Tumour Model Repositories, FP7-ICT-2009.5.4). It is is a predominantly discrete entity -discrete event, clinically-oriented multiscale cancer model. A ‘‘top-down’’ simulation approach has been formulated. The approach method starts from the macroscopic imaging data representing a high scale/level of tumour biology and proceeds towards lower scales/levels. The clinical orientation of the model has been a fundamental guiding principle throughout its development. Available medical data is exploited, in order to support patient-individualized modelling. The model developed has been embedded in a complex algorithmic system and a bioengineering tool denoted by the term “Oncosimulator”. A thorough cross-method sensitivity analysis of the model has been performed, revealing the most determinant biological mechanisms in terms of tumour aggressiveness and therapy outcome. The outcome of this work has provided important insight into the biology of cancer dynamics. Initial results of free growth and response to chemotherapy have been produced and judged as reasonable, thus supporting the validity of the model Successful model adaptation to real clinical cases in the context of the SIOP/GPOH clinical trial guided by a sensitivity analysis has been achieved and published. In order to validate the model, the available pre- and post-surgery clinical data (imaging and histopathological) are used in combination with available literature data. The potential to readily exploit additional data available in the context of clinical trials, thereby narrowing the window of possible solutions, is a particularly distinctive feature of the model. The model is under continuous refinement, optimization and extension in the framework of pertinent clinical trials.
10
Κολοκοτρώνη, Ελένη. "Υπολογιστικές προσομοιώσεις διαγνωστικών και θεραπευτικών τεχνικών που αφορούν σε φυσιολογικά και παθολογικά κυτταρικά συστήματα." Thesis, 2013. http://hdl.handle.net/10889/7221.
Full textAbstract:
Η διατριβή αφορά την ανάπτυξη και υλοποίηση ενός τετραδιάστατου, διακριτού μοντέλου προσομοίωσης της συμπεριφοράς καρκινικών κυτταρικών συστημάτων σε ελεύθερη ανάπτυξη και της απόκρισής τους σε χημειοθεραπευτική ή και ακτινοθεραπευτική αγωγή. Υλοποιήθηκαν δύο εκδοχές του μοντέλου: η χωρική και η μη χωρική προσέγγιση. Η χωρική προσέγγιση αναφέρεται στην τετραδιάστατη προσομοίωση συμπαγών όγκων. Η μη χωρική προσέγγιση βρίσκει εφαρμογή στην περίπτωση μη συμπαγών όγκων, καθώς και συμπαγών όγκων, όταν δεν δίνεται έμφαση στη χωρική εξέλιξή τους. Η ερευνητική εργασία έχει επικεντρωθεί σε τρεις τύπους καρκινικών όγκων: καρκίνος του μαστού, καρκίνος του πνεύμονα και πολύμορφο γλοιοβλάστωμα και σε θεραπευτικά σχήματα χορήγησης των σκευασμάτων: επιρουβικίνη (epirubicin), τεμοζολομίδη (temozolomide), σισπλατίνη (cisplatin), γεμσιταμπίνη (gemcitabine), βινορελμπίνη (vinorelbine) και δοσεταξέλη (docetaxel). Σκοπός της εργασίας είναι η ανάπτυξη ενός εργαλείου για την αξιόπιστη υποστήριξη ιατρών στη λήψη αποφάσεων σχετικά με την επιλογή θεραπευτικών σχημάτων και την εξατομικευμένη βελτιστοποίηση της θεραπευτικής αγωγής.
Η αφετηρία είναι η μοντελοποίηση του κυτταρικού κύκλου και των πιθανών μεταβάσεων μεταξύ των καταστάσεων που μπορεί να βρεθεί ένα κύτταρο. Το μοντέλο βασίζεται στην υπόθεση ότι ο καρκινικός όγκος διατηρείται από μια συγκεκριμένη κατηγορία κυττάρων, τα καρκινικά βλαστικά κύτταρα (cancer stem cells), και έχει επεκταθεί ώστε να περιλαμβάνει σε μεγαλύτερη λεπτομέρεια διάφορους βιολογικούς μηχανισμούς σε μοριακό (πχ. εκφράσεις γονιδίων) και κυτταρικό επίπεδο. Ο μηχανισμός δράσης, η φαρμακοκινητική και η φαρμακοδυναμική των θεωρούμενων σκευασμάτων έχουν μελετηθεί βιβλιογραφικά και έχουν ενσωματωθεί στο μοντέλο. Επίσης, το μοντέλο έχει αναπτυχθεί ώστε να λαμβάνει υπόψη του την κλινική εικόνα του ασθενούς με χρήση εξατομικευμένων κλινικών δεδομένων, όπως απεικονιστικά δεδομένα (π.χ. CT, MRI, PET), ιστοπαθολογικά δεδομένα (π.χ. τύπος όγκου, βαθμός διαφοροποίησης) και μοριακά δεδομένα (π.χ. έκφραση γονιδίων).
Στα πλαίσια της διατριβής πραγματοποιούνται έλεγχοι αξιοπιστίας και εκτενείς παραμετρικές μελέτες για την αποσαφήνιση της ευαισθησίας του μοντέλου στη διακύμανση των παραμέτρων του τόσο κατά την προσομοίωση της ελεύθερης ανάπτυξης όσο και κατά την εφαρμογή της χημειοθεραπευτικής αγωγής. Η ποσοτική αξιολόγηση, προσαρμογή και βελτιστοποίηση του μοντέλου πραγματοποιείται στα πλαίσια των ευρωπαϊκών ερευνητικών προγραμμάτων ACGT (Advancing Clinicogenomic Trials on Cancer, FP6-2005-IST-026996), ContraCancrum (Clinically Oriented Cancer Multilevel Modelling, FP7-ICT-2007-2-223979) και P-medicine (From data sharing and integration via VPH models to Personalized medicine, FP7-ICT-2009-6-270089) μέσω της αξιοποίησης πραγματικών κλινικών δεδομένων. Στην παρούσα διατριβή παρουσιάζονται τα αποτελέσματα της προσαρμογής του μοντέλου σε κλινικά δεδομένα του καρκίνου του μαστού, του καρκίνου του πνεύμονα και του πολύμορφου γλοιοβλαστώματος. Επιπλέον, διάφορες εκδόσεις του μοντέλου έχουν αξιοποιηθεί για ‘την επάνδρωση’ μιας ευρωπαϊκής βάσης μοντέλων για τον καρκίνο, που υλοποιείται στα πλαίσια του ευρωπαϊκού ερευνητικού προγράμματος TUMOR (Transatlantic Tumour Model Repositories, FP7-ICT-2009-5-247754). Το μοντέλο υλοποιείται σε γλώσσα προγραμματισμού C++.In the present thesis, a clinically oriented, multiscale, discrete simulation model of cancer free growth and response to chemotherapy and/or radiotherapy is presented and investigated. Two versions of the model have been implemented: the spatial and the non spatial approach. The spatial model concerns the spatiotemporal evolution of solid tumours, whereas the non spatial model can be applied in the case of non solid cancers, as well as solid tumours, when no emphasis is put on the spatial features of a tumour evolution. The research work has been focused on the paradigms of early breast cancer treated with the single agent epirubicin, primary lung cancer treated with various combinations of cisplatin, gemcitabine, vinorelbin and docetaxel and glioblastoma multiforme treated with combined modality treatment using radiation and chemotherapy with temozolomide. The goal is to end up with a reliable simulation system able to assist clinicians in selecting the most appropriate therapeutic pattern, extracted from several candidate therapeutic schemes in the context of patient individualized treatment optimization. The model incorporates the biological mechanisms of cell cycling, quiescence, recruitment (reentry into the cell cycle), differentiation and death. It is based on the well documented assumption that tumour sustenance is due to the existence of cancer stem cells, i.e. cells which have the ability to preserve their own population, as well as give birth to cells that follow the path towards terminal differentiation. Furthermore, the mechanism of action, pharmacokinetics and pharmacodynamics of all considered agents have been bibliographically studied and incorporated into the model. Finally, the model has been developed to support and incorporate individualized clinical data such as imaging data (e.g. CT, MRI, PET slices, possibly fused), including the definition of the tumour contour and internal tumour regions (proliferating, necrotic), histopathologic (e.g., type of tumour) and genetic data (e.g., gene expression). An exhaustive and in-depth examination of the model behaviour with respect to the variation of its input parameters has been performed, in order to determine the impact of its parameters, guarantee a biologically relevant virtual tumour behaviour and enlighten aspects of the interplay and possible interdependencies of the biological mechanisms modeled. Finally, the model has been quantitativily validated and adaptated in the framework of the ACGT (Advancing Clinicogenomic Trials on Cancer, FP6-2005-IST-026996), ContraCancrum (Clinically Oriented Cancer Multilevel Modelling, FP7-ICT-2007-2-223979) and P-medicine (From data sharing and integration via VPH models to Personalized medicine, FP7-ICT-2009-6-270089) European Commission-funded projects by exploiting real clinical data. In the present thesis, the clinical adaptation of the model focuses on breast cancer, lung cancer and glioblastoma multiforme clinical cases. Moreover, various versions of the model have been uploaded to the EU cancer model repository developed by the TUMOR (Transatlantic Tumour Model Repositories, FP7-ICT-2009-5-247754) European Commission-funded project. The model has been developed in the C++ programming language.
Book chapters on the topic "In silico oncology"
1
Cheng, Feixiong. "In Silico Oncology Drug Repositioning and Polypharmacology." In Methods in Molecular Biology, 243–61. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-8868-6_15.
Full text
2
Stamatakos, Georgios. "Top-Down Multiscale Simulation of Tumor Response to Treatment in the Context of In Silico Oncology. The Notion of Oncosimulator." In New Challenges for Cancer Systems Biomedicine, 355–75. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2571-4_19.
Full text
3
Stamatakos, G. S., E. Kolokotroni, D. Dionysiou, E. Georgiadi, and S. Giatili. "In Silico oncology: a top-down multiscale simulator of cancer dynamics. Studying the effect of symmetric stem cell division on the cellular constitution of a tumour." In IFMBE Proceedings, 1830–33. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-03882-2_486.
Full text
4
Minovski, Nikola, and Marjana Novič. "Integrated in Silico Methods for the Design and Optimization of Novel Drug Candidates." In Oncology, 434–81. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0549-5.ch016.
Full textAbstract:
Although almost fully automated, the discovery of novel, effective, and safe drugs is still a long-term and highly expensive process. Consequently, the need for fleet, rational, and cost-efficient development of novel drugs is crucial, and nowadays the advanced in silico drug design methodologies seem to effectively meet these issues. The aim of this chapter is to provide a comprehensive overview of some of the current trends and advances in the in silico design of novel drug candidates with a special emphasis on 6-fluoroquinolone (6-FQ) antibacterials as potential novel Mycobacterium tuberculosis DNA gyrase inhibitors. In particular, the chapter covers some of the recent aspects of a wide range of in silico drug discovery approaches including multidimensional machine-learning methods, ligand-based and structure-based methodologies, as well as their proficient combination and integration into an intelligent virtual screening protocol for design and optimization of novel 6-FQ analogs.
5
"▪ In Silico Oncology: Part II—Clinical Requirements Regarding In Silico Oncology." In Multiscale Cancer Modeling, 462–71. CRC Press, 2010. http://dx.doi.org/10.1201/b10407-24.
Full text
6
Thai, Khac-Minh, Quoc-Hiep Dong, Thi-Thanh-Lan Nguyen, Duy-Phong Le, Minh-Tri Le, and Thanh-Dao Tran. "Computational Approaches for the Discovery of Novel Hepatitis C Virus NS3/4A and NS5B Inhibitors." In Oncology, 482–518. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0549-5.ch017.
Full textAbstract:
Nonstructural 5B (NS5B) polymerase and Nonstructural 3/4A (NS3/4A) protease have proven to be promising targets for the development of anti-HCV (Hepatitis C Virus) agents. The NS5B polymerase is of paramount importance in HCV viral replication; therefore, employing NS5B inhibitors was considered an effective way for the treatment of HCV. Identifying inhibitors against NS3/4A serine protease represents another attractive approach applied in anti-HCV drug discovery, which is evidenced by its crucial role of in the biogenesis of the viral replication activity. In this chapter, many different computational approaches including Quantitative Structure-Activity Relationship (QSAR) and virtual screening in anti-HCV drug discovery were considered and discussed in detail. Virtual Screening (VS) techniques, including ligand-based and structure-based, and QSAR have been utilized for the discovery of NS5B inhibitors. Moreover, using various in silico protocols and workflows, a number of studies have been conducted with an aim of identifying potential NS3/4A blockage agents.
7
Mohan, C. Gopi, and Shikhar Gupta. "QSAR Models towards Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease." In Oncology, 591–636. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0549-5.ch022.
Full textAbstract:
Alzheimer's Disease (AD) is a multifactorial neurological syndrome with the combination of aging, genetic, and environmental factors triggering the pathological decline. Interestingly, the importance of the Acetylcholinesterase (AChE) enzyme has increased due to its involvement in the ß-amyloid peptide fibril formation during AD pathogenesis. In silico technique, QSAR has proven its usefulness in pharmaceutical research for the design/optimization of new chemical entities. Further, QSAR method advanced the scope of rational drug design and the search for the mechanism of drug action. It is a well-established fact that the chemical and pharmaceutical effects of a compound are closely related to its physico-chemical properties, which can be calculated by various methods from the compound structure. This chapter focuses on different Quantitative Structure-Activity Relationship (QSAR) studies carried out for a variety of cholinesterase inhibitors for the treatment of AD. These predictive models will be potentially used for further designing better and safer drugs against AD.
8
"▪ In Silico Oncology: Part I—Clinically Oriented Cancer Multilevel Modeling Based on Discrete Event Simulation." In Multiscale Cancer Modeling, 432–61. CRC Press, 2010. http://dx.doi.org/10.1201/b10407-23.
Full textConference papers on the topic "In silico oncology"
1
Athanaileas, Theodoros, Andreas Menychtas, Dimitra Dionysiou, Georgios Stamatakos, Dimitra Kaklamani, Theodora Varvarigou, and Nikolaos Uzunoglu. "A Grid-Enabled Toolkit for In Silico Oncology Simulations." In 1st International ICST Conference on Simulation Tools and Techniques for Communications, Networks and Systems. ICST, 2008. http://dx.doi.org/10.4108/icst.simutools2008.3042.
Full text
2
Psakhie, S. G., and A. A. Tsukanov. "Molecular level in silico studies for oncology. Direct models review." In PHYSICS OF CANCER: INTERDISCIPLINARY PROBLEMS AND CLINICAL APPLICATIONS: Proceedings of the International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications (PC IPCA’17). Author(s), 2017. http://dx.doi.org/10.1063/1.5001637.
Full text
3
Li, Ying, Jyothi Venkatiahgari, Liping Jin, Donavan T. Cheng, and James Cai. "In Silico Target Portal: An integrated Oncology target discovery web portal." In 2012 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2012. http://dx.doi.org/10.1109/bibm.2012.6392636.
Full text
4
Marinova, Maria, and Vladimir Lazarov. "Comparative analysis of workflow platform in support of in silico oncology." In PROCEEDINGS OF THE 45TH INTERNATIONAL CONFERENCE ON APPLICATION OF MATHEMATICS IN ENGINEERING AND ECONOMICS (AMEE’19). AIP Publishing, 2019. http://dx.doi.org/10.1063/1.5133487.
Full text
5
Nwankwo, Iheanyi S., Marc S. Stauch, Alan Dahi, and Nikolaus P. Forgo. "Legal and ethical aspects of In Silico medicine." In 2014 6th International Advanced Research Workshop on "In Silico Oncology and Cancer Investigation". IEEE, 2014. http://dx.doi.org/10.1109/iarwisoci.2014.7034647.
Full text
6
Neri, Elias, and Wouter Dhaeze. "Incorporating data protection in In Silico research: A case of the CHIC project." In 2014 6th International Advanced Research Workshop on "In Silico Oncology and Cancer Investigation". IEEE, 2014. http://dx.doi.org/10.1109/iarwisoci.2014.7034643.
Full text
7
Stamatakos, Georgios S., Eleni Kolokotroni, Dimitra Dionysiou, Christian Veith, Yoo-Jin Kim, Astrid Franz, Kostas Marias, Joerg Sabczynski, Rainer Bohle, and Norbert Graf. "In silico oncology: Exploiting clinical studies to clinically adapt and validate multiscale oncosimulators." In 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2013. http://dx.doi.org/10.1109/embc.2013.6610806.
Full text
8
"[Title page]." In 2014 6th International Advanced Research Workshop on "In Silico Oncology and Cancer Investigation". IEEE, 2014. http://dx.doi.org/10.1109/iarwisoci.2014.7034625.
Full text
9
"[Copyright notice]." In 2014 6th International Advanced Research Workshop on "In Silico Oncology and Cancer Investigation". IEEE, 2014. http://dx.doi.org/10.1109/iarwisoci.2014.7034626.
Full text
10
"Organizing Committee." In 2014 6th International Advanced Research Workshop on "In Silico Oncology and Cancer Investigation". IEEE, 2014. http://dx.doi.org/10.1109/iarwisoci.2014.7034627.
Full text